KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of SalesDeferred RevenueEmployee StatisticsGovernment Contracts Revenue By CategoryGrants And Other Revenue By CategoryGrants And Other Revenue By Category AnnualGross Margin %Gross ProfitIncome (Loss) Before Income TaxOperating Expense SegregationOpex As % Of Total Revenue %Product Sales Revenue By GeographyProduct Sales Revenue By Geography AnnualProfitabilityProfitability %Profitability AnnualProfitability Annual %Property And Equipment, Net BreakdownPurchase Commitments AnnualRemaining Performance ObligationRemaining Performance Obligations AnnualRevenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Gross Profit (2016 - 2025)

Novavax has reported Gross Profit over the past 10 years, most recently at $125.0 million for Q4 2025.

  • Quarterly results put Gross Profit at $125.0 million for Q4 2025, up 142.12% from a year ago — trailing twelve months through Dec 2025 was $986.2 million (up 105.71% YoY), and the annual figure for FY2025 was $1.1 billion, up 119.1%.
  • Gross Profit for Q4 2025 was $125.0 million at Novavax, up from $48.9 million in the prior quarter.
  • Over the last five years, Gross Profit for NVAX hit a ceiling of $688.8 million in Q1 2022 and a floor of -$85.2 million in Q2 2022.
  • Median Gross Profit over the past 5 years was $167.7 million (2022), compared with a mean of $216.6 million.
  • Biggest five-year swings in Gross Profit: plummeted 128.57% in 2022 and later skyrocketed 1783.45% in 2025.
  • Novavax's Gross Profit stood at $222.2 million in 2021, then dropped by 20.96% to $175.6 million in 2022, then fell by 22.36% to $136.4 million in 2023, then crashed by 62.13% to $51.6 million in 2024, then soared by 142.12% to $125.0 million in 2025.
  • The last three reported values for Gross Profit were $125.0 million (Q4 2025), $48.9 million (Q3 2025), and $159.7 million (Q2 2025) per Business Quant data.